^
    1year
    Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Chongqing Precision Biotech Co., Ltd | Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha)
    |
    CD123 positive • CD123 expression
    |
    CD123 CAR-T cell therapy
    1year
    CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=45, Recruiting, Chongqing Precision Biotech Co., Ltd | Trial completion date: Jul 2022 --> Jul 2024 | Trial primary completion date: Dec 2021 --> Dec 2023
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha)
    |
    CD123 positive • CD123 expression
    |
    CD123 CAR-T cell therapy
    4years
    Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Chongqing Precision Biotech Co., Ltd
    Clinical • New P1/2 trial
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha)
    |
    CD123 positive
    |
    CD123 CAR-T cell therapy
    over4years
    CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=45, Recruiting, Chongqing Precision Biotech Co., Ltd
    New P1/2 trial • CAR T-Cell Therapy
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha)
    |
    CD123 positive
    |
    CD123 CAR-T cell therapy